Table 6.
Overall response rate and PFS in 6 randomized trials comparing gemcitabine to gemcitabine plus fluoropyrimidine
| Reference | Year | n | Treatment regimen | ORR (%) | p | Median PFS/TTP (mo) | p |
| Berlin | 2002 | 162 | Gemcitabine | 5.6 | -- | 2.2 | |
| 160 | Gemcitabine + 5-FU (bolus) | 6.9 | 3.4 | 0.022 | |||
| Riess | 2005 | 238 | Gemcitabine | 7.2 | -- | 3.5 | 0.44 |
| 235 | Gemcitabine + 5-FU (infusional) | 4.8 | 3.5 | ||||
| DiCostanzo | 2005 | 48 | Gemcitabine | 8 | -- | 3.5 | -- |
| 43 | Gemcitabine + 5-FU (CI) | 11 | 4.5 | ||||
| Scheithauer | 2003 | 42 | Gemcitabine | 14 | -- | 4.0 | -- |
| 41 | Gemcitabine + Capecitabine | 17 | 5.1 | ||||
| Herrmann | 2005 | 159 | Gemcitabine | 7.9 | -- | 4.0 | 0.207 |
| 160 | Gemcitabine + Capecitabine | 10.1 | 4.8 | ||||
| Cunningham | 2005 | 266 | Gemcitabine | 7.1 | 0.008 | na | na |
| 267 | Gemcitabine + Capecitabine | 14.2 | na |
ORR = overall response rate; PFS = progression-free survival; TTP = time-to-progression; na = data not available; CI = continuous infusion; 5-FU = 5-fluorouracil;